Pharmacovigilance in the 21st Century: New Systematic Tools for an Old Problem

The large number of adverse‐event reports generated by marketed drugs and devices argues for the application of validated computerized algorithms to supplement traditional methods of detecting adverse‐event signals. Difficulties in accurately estimating patient exposure and background rates for a given event in a specific population hinder risk estimation in spontaneous adverse‐event databases. The United States Food and Drug Administration (FDA) is evaluating a Bayesian data mining system called Multi‐item Gamma Poisson Shrinker (MGPS) to enhance the FDA's ability to monitor the safety of drugs, biologics, and vaccines after they have been approved for use. The MGPS computes adjusted higher‐than‐expected reporting relationships between drugs and adverse events across 35 years of data relative to internal background rates. The MGPS can also adjust for random noise by using a model derived from the data, and corrects for temporal trends and confounding related to age, sex, and other variables by stratifying over 900 categories. Signals can then be compared with or used in conjunction with other sources (e.g. clinical trials, general practice databases) to further study the adverse‐event risk. The example of pancreatitis risk with atypical antipsychotics, valproic acid, and valproate is used to discuss the strengths and limitations of MGPS versus traditional methods. Validated data mining techniques offer great promise to enhance pharmacovigilance practices.

[1]  P. Doraiswamy,et al.  Olanzapine‐Associated Diabetes Mellitus , 2002, Pharmacotherapy.

[2]  K. A. Huston Achilles tendinitis and tendon rupture due to fluoroquinolone antibiotics. , 1994, The New England journal of medicine.

[3]  A. Szarfman,et al.  More on fluoroquinolone antibiotics and tendon rupture. , 1995, The New England journal of medicine.

[4]  M. Hauben Application of an Empiric Bayesian Data Mining Algorithm to Reports of Pancreatitis Associated with Atypical Antipsychotics , 2004, Pharmacotherapy.

[5]  A Lawrence Gould,et al.  Practical pharmacovigilance analysis strategies. , 2003, Pharmacoepidemiology and drug safety.

[6]  Robert T. O'Neill,et al.  Some US Food and Drug Administration Perspectives on Data Mining for Pediatric Safety Assessment , 2001 .

[7]  William DuMouchel,et al.  Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .

[8]  V. Miller,et al.  Monitoring of long-term toxicities of HIV treatments: an international perspective , 2003, AIDS.

[9]  R. O’Neill,et al.  Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database , 2002, Drug safety.

[10]  P. Doraiswamy,et al.  Risperidone‐Associated Diabetes Mellitus: A Pharmacovigilance Study , 2003, Pharmacotherapy.

[11]  William DuMouchel,et al.  Empirical bayes screening for multi-item associations , 2001, KDD '01.

[12]  P. Doraiswamy,et al.  Pancreatitis Associated with Atypical Antipsychotics: From the Food and Drug Administration's MedWatch Surveillance System and Published Reports , 2003, Pharmacotherapy.

[13]  D J Graham,et al.  Temafloxacin syndrome: review of 95 cases. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.